Mitigating Recurrence Risk: A Multisite QI Initiative to Improve Clinical Outcomes and Management in Patients With High-Risk HR+/HER2- EBC

This educational program aims to enhance the knowledge, competence, and confidence of healthcare professionals in assessing and managing high-risk HR+/HER2- EBC by focusing on ways to effectively communicate risk assessment to patients and measures to implement optimal therapeutic strategies to reduce recurrence risk and optimize treatment outcomes.

Share

Program Content

Activities

Discussion about High-Risk HR+/HER2- EBC
Discussing Newer Treatment Options and What to Expect With Patients With High-Risk HR+/HER2- Early Breast Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 29, 2024

Expires: October 28, 2025

Faculty

cover img faculity

Angela Bassani

Patient

cover img faculity

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC, in partnership with Q Synthesis and The American Society of Breast Surgeons Foundation

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

Q Synthesis LLC

ProCE Banner

The American Society of Breast Surgeons Foundation

ProCE Banner